The YCC Protocol Review and Monitoring System (PRMS) provides critical oversight of all cancer clinical trials conducted in the YCC. The PRMS. is made up of three main elements, which include the Clinical Research Steering Committee (CRSC), the Protocol Review Committee (PRC), and the Quality Assurance, Compliance, and Safety Committee (QUACS). The CRSC and PRC are responsible for scientific prioritization and review of clinical trials prior to activation. The QUACS focuses on data and safety monitoring and closely monitors scientific progress, accrual of activated trials, overall quality control and patient monitoring, and deals with all issues relating to quality assurance and auditing. The QUACS functions and activities are described in more detail in Section 12. An Oversight Committee composed of the YCC Director and Senior Leadership provides a mechanism for appeal of decisions made through the PRMS. Since the last CCSG application in 1998, the PRMS has been significantly re-organized, enhanced, and expanded to provide a more rigorous scientific review of proposed clinical trials;to enhance and ensure appropriate statistical input during the review of clinical trials;to provide a comprehensive process for prioritization of clinical trials, and in particular, to allocate YCC resources to support investigator-initiated clinical trials;to ensure timely scientific monitoring of activated trials;and to enforce closure of poorly accruing trials. A new YCC Office of Protocol Review and Monitoring (OPRM) was created to provide and unify administrative support to the three PRMS Committees. A senior physician, Dr. Mario Sznol, with extensive experience in conducting and monitoring clinical research was recruited to provide medical leadership of the OPRM and to chair the PRC and QUACS. To complement physician leadership in this office, an experienced senior clinical research professional, Susan Anderson R.N., was appointed to be Operations Director of the OPRM. The OPRM supports the activities of the CRSC, PRC and QUACS Committees;maintains a tracking database for protocol reviews and approval, safety data submission, annual review submissions, and compliance audits;generates minutes for the CRSC, PRC and QUACS meetings;maintains a protocol priority list;tracks and files correspondence with investigators;contains the auditing function of the YCC, and conducts a rigorous training program for the clinical research staff in managing clinical trials and complying with regulatory requirements. A major initiative of the OPRM was to expand the membership and expertise of the PRC and to incorporate and establish a robust process for statistical input and review of trial. Future plans include recruitment and training of new PRC members, as well as training of fellows and junior faculty in methods of clinical research and review of clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-31
Application #
7916707
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
31
Fiscal Year
2009
Total Cost
$57,922
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :

Showing the most recent 10 out of 675 publications